Tim Hudson is one of the Giants’ “chief targets”

8 Comments

Tim Hudson is one of the few free agents I can remember who actually signed with a team near where he grew up, so it’s probably not smart to totally dismiss the idea of him wanting to stay in Atlanta. But the dude was young and rich in the Bay Area once upon a time too, and probably enjoyed it, so maybe — if a sense of “home” matters to him — this from Hank Schulman of the San Francisco Chronicle makes sense:

One of the Giants’ chief pitching targets is Tim Hudson. Two potential obstacles to signing him appear to be non-issues now. First, sources said, the Alabama native and Georgia resident is willing to move across the country again to pitch for the right team. Second, the Braves apparently offered him a contract with a significantly smaller salary than he earned last year, one he is not inclined to accept.

I really don’t get the Braves lowballing Hudson after so many people on the team — players and manager Fredi Gonzalez — have talked about wanting him back. But then again, if we’ve learned anything this week it’s that the Braves are gonna zig when you think they’ll zag.

But of course in all seriousness, hometowns and the desires of people without skin in the game matter very little when it comes to free agency. It’s almost always about the money.

 

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.